Morgan Stanley Protara Therapeutics, Inc. Call Options Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TARA
# of Institutions
65Shares Held
29.8MCall Options Held
49.5KPut Options Held
181K-
Ra Capital Management, L.P. Boston, MA3.4MShares$14.1 Million0.29% of portfolio
-
Janus Henderson Group PLC London, X02.27MShares$9.43 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.25MShares$9.34 Million0.02% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A62.09MShares$8.67 Million0.02% of portfolio
-
Opaleye Management Inc. Boston, MA1.83MShares$7.57 Million1.88% of portfolio
About Protara Therapeutics, Inc.
- Ticker TARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,267,400
- Market Cap $46.8M
- Description
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...